Literature DB >> 31426691

Novel mutation in the periaxin gene causal to Charcot-Marie-Tooth disease type 4F.

Yu-Hui Chen1, Hua Zhang1, Ling-Bing Meng1, Xiao-Yan Tang2, Tao Gong1, Jian Yin1.   

Abstract

Charcot-Marie-Tooth (CMT) disease is the most common hereditary neuropathy. Mutations in the periaxin gene (PRX) can cause CMT type 4F, an autosomal recessive neuropathy, which is clinically characterized by slowly progressive distal muscle atrophy and weakness, with pes cavus deformity of the foot, and the absence of deep tendon reflexes. To date, dozens of reports of PRX mutations have been published worldwide, but none have been reported in Chinese patients. Here, we describe a 14-year-old Chinese boy with neuropathy characterized by slowly progressive limb weakness and atrophy, as well as sensory ataxia, whose cerebrospinal protein levels were 1627 mg/L. Genetic analysis identified a novel homozygous mutation, c.1174C>T (p.R392X), in exon 6 of PRX, which is the first case of its kind recorded in China.

Entities:  

Keywords:  Charcot–Marie–Tooth disease; c.1174C>T (p.R392X); cerebrospinal protein; muscle atrophy; periaxin; sensory ataxia

Mesh:

Substances:

Year:  2019        PMID: 31426691      PMCID: PMC7581982          DOI: 10.1177/0300060519862064

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


Introduction

The periaxin gene (PRX) is located on chromosome 19q13.13–13.2 and encodes a myelin-associated protein that plays an important role in maintaining the stability of myelin.[1] Periaxin binds peripheral nerve fibers to the cytoskeleton and functions in the development of peripheral nerve fibers.[2] Abnormal PRX expression caused by PRX mutations causes poor myelin generation, demyelination, and other peripheral nerve changes.[1,3-7] To date, dozens of patients with PRX mutations have been reported worldwide, including those with nonsense, missense, and frameshift mutations.[8] However, none of these mutations have been found in Chinese patients. In this paper, we report a novel homogenous point nonsense mutation in PRX in a 14-year-old Chinese boy.

Case Report

The patient is a 14-year-old boy who is the second child of healthy, nonconsanguineous Chinese parents. He has a healthy older sister. He started to walk at the age of 1.5 years. Although his gait was clumsy and he was prone to falling down, this did not greatly affect his daily life. His symptoms progressed slowly. At the age of 7 years, the muscles in his limbs were so weak that he had difficulty standing up from a squatting position and could not pick up food with chopsticks. He was also noted to have scoliosis and pes cavus. At the age of 14, he can still walk independently and feed himself with a spoon. Neurological examination revealed a thin body habitus, scoliosis, and bilateral pes cavus. He showed severe weakness and foot eversion with no proximal muscle involvement. His muscle weaknesses were much more pronounced distally (a 4/5 Medical Research Council score) than proximally (5/5). Sensitivities to pinprick, touch, position, and vibration decreased distally up to the knee and elbow level; the vibration sensation was more severely disturbed than pain sensations in all limbs. Sensory ataxia and a positive Romberg sign were also present. Deep tendon reflexes were absent and pathologic reflexes were negative. His gait was slightly broad-based and unsteady. Blood, urine routine, and stool tests were negative, and his coagulation function and blood biochemical tests, including hepatic, renal function, glucose, lipid, and ion concentrations, were normal. Tumor biomarkers and autoimmune antibodies were negative, and serum M protein was also negative. Hepatitis B and C, syphilis, and HIV tests were all negative. A lumbar puncture revealed that the cerebrospinal fluid (CSF) pressure was 175 mmH20 (normal range, 80–180 mm H20), CSF leukocytes were 1/mm3 (normal range, 0–5/mm3), CSF protein levels were greatly elevated at 1627 mg/L (normal range, 150–450 mg/L), and the oligoclonal band of CSF was negative. A chest X-ray, electrocardiogram, and transthoracic echocardiography found no dysfunction. One cyst (1.1 × 0.8 mm) was detected in the right kidney, but the other organs were normal. Brain magnetic resonance imaging (MRI) was also normal. Spinal MRI detected spinal scoliosis, but no abnormal signal was found. Fundus examination was normal. Electrophysiologic examinations revealed absent compound muscle action potentials (CMAPs) in the median, ulnar, peroneal, and tibial nerves, and absent sensory nerve action potentials in the median, ulnar, and sural nerves. Motor nerve conduction velocity (NCV) and sensory nerve conduction were absent in all peripheral nerves. A needle electromyogram showed insertional activity (+), spontaneous activity (+), and severely reduced recruitment of motor unit potentials. Motor unit action potentials had a prolonged duration and increased amplitude (15.5 ms and 2793 µV, respectively, in the tibialis anterior muscle, and 9.1 ms and 1174 µV, respectively, in the first dorsal interosseous muscle). The electromyographic examination was consistent with chronic reinnervation. Electrophysiologic examinations of the patient’s parents and sister showed that their sensory nerve conduction and motor nerve conduction were within normal ranges (Table 1). The patient and his parents refused muscle and nerve biopsy tests.
Table 1.

Electrophysiologic manifestation of the patient and his family members.

NervesItemsPatient(14 years)Father(48 years)Mother(47 years)Sister(20 years)
Motor
 Right/left ulnarDistal latency (ms)NR2.7/2.52.52.1
MNCV (m/s)NR54.1/57.364.062.7
Amplitude (mV)NR5.2/4.811.49.9
 Right/left medianDistal latency (ms)NR3.1/3.13.32.6
MNCV (m/s)NR55.7/57.461.562.3
Amplitude (mV)NR6.4/6.92.97.8
 Right/left peronealDistal latency (ms)NR3.3/3.62.73.1/3.8
MNCV (m/s)NR41.6/45.347.948.6/47.7
Ampl (mV)NR6.0/4.65.77.8/6.2
 Right/left tibialDistal latency (ms)NR4.1/3.93.13.3
MNCV (m/s)NR40.1/41.645.851.1
Amplitude (mV)NR8.7/9.911.817.3
Sensory
 Right/left ulnarSCV (m/s)NR57.1/59.958.7/55.959.3/54.4
Amplitude (µV)NR14.4/26.642.6/44.345.1/55.9
 Right/left medianSCV (m/s)NR62.2/62.556.1/54.361.2/56.4
Amplitude (µV)NR27.3/18.239.8/44.164.0/47.4
 Right/left peronealSCV (m/s)NR45.7/49.449.5/48.052.6/53.7
Amplitude (µV)NR8.5/7.516.8/22.835.0/9.2
 Right/left tibialSCV (m/s)NR47.9/50.853.1/51.049.5/49.0
Amplitude (µV)NR6.4/7.913.9/11.325.6/34.0

MCV = motor nerve conduction velocity; NR=not recordable; SCV=sensory nerve conduction velocity.

Electrophysiologic manifestation of the patient and his family members. MCV = motor nerve conduction velocity; NR=not recordable; SCV=sensory nerve conduction velocity. Because Charcot–Marie–Tooth disease (CMT) is the most common hereditary neuropathy with infantile onset and limb atrophy, we screened 39 CMT-related genes using high-throughput sequencing technology. This identified a homozygous mutation, c.1174C>T (p.R392X), in exon 6 of PRX that was the most likely cause of disease in the patient (Figure 1). This research conformed to the Declaration of Helsinki and was authorized by the Human Ethics and Research Ethics Committees of Beijing Hospital. Informed consent was obtained from the patient.
Figure 1.

Causative homozygous point mutation, c.1174C>T (p.R392X), in exon 6 of PRX.

Causative homozygous point mutation, c.1174C>T (p.R392X), in exon 6 of PRX.

Discussion

PRX on chromosome 19q13.13-q13.2 encodes periaxin, which is a vital structural protein for correct maintenance of the peripheral nerve myelin sheath and for Schwann cell compartmentalization. Periaxin has two isoforms generated by alternative splicing: L-periaxin and S-periaxin.[1,2] L-periaxin is composed of 1461 amino acids and is located mainly in the cell membrane and nucleus, while S-periaxin contains only 147 amino acids and is mostly found in the cytoplasm. In immature myelin, periaxin proteins are typically located near the axon membrane; in mature myelin, they are further away from the axon membrane. L-periaxin has four characteristic domains: PDZ, nuclear localization signal (NLS), repeat, and acidic.[9-11] The PDZ domain interacts with proteins, peptide ligands, and lipidosomes to form homogenous or heterogeneous dimers,[12] while the NLS domain mediates the export of L-periaxin from the nucleus to the cytoplasm. L-periaxin stabilizes the dystroglycan–glycoprotein complex by directly interacting with dystrophin-related protein 2, linking the basal lamina to the Schwann cell cytoskeleton and contributing, together with utrophin and extracellular laminin, to the correct compartmentalization and elongation of Schwann cells.[13,14] Acidic domains may mediate protein–protein interactions and enable L-periaxin to bind to the cytoskeleton of Schwann cells or transmit signals, leading to stabilized myelin formation.[15] To date, dozens of patients have been described with around 30 different PRX mutations (Figure 2). These include nonsense, missense, point, and frameshift mutations,[1,3,4,15-21,22] and most affect the synthesis of L-periaxin. Eleven pathogenic point mutations have been detected,[1,3,4,16-22] of which one is a missense mutation[15,18] while the remainder are nonsense mutations. Twenty-two patients were reported to harbor homozygous nonsense/missense mutations,[1,3,4,16-20] of whom 14 are from three families[1,3,4,17] and the remaining eight are sporadic. Half of the 22 patients had consanguinity. Ten of the PRX frame-shift mutation loci are pathogenic and affect 30 patients.[5,15-17,22-25] Twenty-four cases are from Reunion Island,[5] suggesting that they derive from the same ancestor. Complex heterozygous mutations are relatively rare, with only six reported cases [8,15,16,21,22] of whom two are from the same family.[16] None of the parents were inbred.
Figure 2.

PRX mutation sites according to the published literature. The same color indicates one patient with two mutation sites.

PRX mutation sites according to the published literature. The same color indicates one patient with two mutation sites. Most patients with PRX mutations have an onset of symptoms as infants or young children while others were middle-aged.[18] The main characteristics include motor retardation, an unsteady gait, atrophy, weakness in proximal and distal muscles, peripheral sensory disorders, deep sensory disturbance, and even sensory ataxia. Additionally, patient extremities lack tendon reflexes, and most patients develop dysmorphic features including scoliosis, kyphosis, and pes cavus. Electrophysiological examination reveals an NCV that is undetectable or less than 10 cm/s, although some patients have a NCV >20 cm/s.[17,18] Neuropathological examination reveals a characteristic decrease of myelin sheath fibers accompanied by hypoplasia of myelin fibers, thin myelin sheaths, and an ‘onion bulb’ appearance.[1,3,4,15-22] Our patient had very high CSF protein levels of 1627 mg/L, which compares with a previous study reporting mildly elevated CSF protein of 580 mg/L.[15] We propose two reasons for this observed high increase of CSF protein. First, PRX is expressed in peripheral nerves where it maintains the function of the peripheral nerve myelin sheath and Schwann cell compartmentalization. Therefore, PRX mutations may impair peripheral neuropathy, leading to peripheral nerve demyelination and hypoplasia of myelin fibers. Second, PRX is also expressed in human cerebral capillary endothelial cells where it establishes endothelial tight junctions and plays an important role in maintaining the brain–blood barrier BBB function and reducing permeability.[26] Therefore, PRX mutations may reduce the BBB function enabling molecules to leak into the CSF. The present study has some limitations. First, we did not investigate the presence of this PRX variant in healthy controls because of limited sources; this should be done in future studies. Second, we did not measure CMAPs in proximal muscles. We propose to detect these in the proximal muscles of future patients if they demonstrate similar symptoms to this present case. In summary, inherited peripheral neuropathy caused by PRX mutations is characterized by early-onset distal limb weakness and atrophy that is more severe in lower than upper limbs. Sensory disturbance is prominent in affected patients, especially deep sensory disturbance, which is the main characteristic of this disease. Most patients have pes cavus, scoliosis, and other skeletal deformities, and most show progressive disease. The oldest patient reported in the literature was 60 years old. Around 29% of patients carrying PRX mutations are disabled;[5] for example, a patient carrying PRX C715X was deaf,[17] PRX D651N was detected in an individual with hoarseness and vocal cord paralysis,[18] while PRX R82fsX96[17] was associated with weakness and atrophy of tongue muscles. Therefore, the possibility of PRX mutations should be considered in patients with distal limb weakness and atrophy associated with sensory disturbance, and further screening of relevant gene loci is needed for diagnosis. To the best of our knowledge, this is the first patient of Chinese origin with a PRX mutation. Additionally, this novel homozygous nonsense mutation, c.1174C>T (p.R392X), in exon 6 of PRX has not been reported before. Although mutation p.R392X has previously been documented as pathogenic in a pair of compound heterozygote nonsense mutations,[21] we consider it to be causative of disease in the present case as a homozygous mutation. PRX mutations may not cause severe early-onset CMT with autosomal recessive inheritance, but the presence of early-onset prominent distal limb weakness should justify genetic testing of PRX mutations. Additionally, CMT patients with extremely low or undetectable sensory and motor nerve conduction and high levels of CSF protein should be considered for PRX screening.
  26 in total

1.  [Charcot-Marie-Tooth disease associated with periaxin mutations (CMT4F): Clinical, electrophysiological and genetic analysis of 24 patients].

Authors:  M Renouil; T Stojkovic; M L Jacquemont; K Lauret; P Boué; A Fourmaintraux; H Randrianaivo; M Tallot; D Mignard; P Roelens; D Tabailloux; R Bernard; F Cartault; E Chane-Thien; O Dubourg; X Ferrer; G Sole; E Fournier; P Latour; A Lacour; C Mignard
Journal:  Rev Neurol (Paris)       Date:  2013-09-05       Impact factor: 2.607

2.  Two PDZ domain proteins encoded by the murine periaxin gene are the result of alternative intron retention and are differentially targeted in Schwann cells.

Authors:  L Dytrych; D L Sherman; C S Gillespie; P J Brophy
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

3.  [Establishment of L-periaxin gene knock-out RSC96 cell line].

Authors:  Min Liang; Tingting Peng; Yawei Shi
Journal:  Sheng Wu Gong Cheng Xue Bao       Date:  2016-12-25

4.  Periaxin mutations cause recessive Dejerine-Sottas neuropathy.

Authors:  C F Boerkoel; H Takashima; P Stankiewicz; C A Garcia; S M Leber; L Rhee-Morris; J R Lupski
Journal:  Am J Hum Genet       Date:  2000-12-15       Impact factor: 11.025

5.  Mapping of a new locus for autosomal recessive demyelinating Charcot-Marie-Tooth disease to 19q13.1-13.3 in a large consanguineous Lebanese family: exclusion of MAG as a candidate gene.

Authors:  V Delague; C Bareil; S Tuffery; P Bouvagnet; E Chouery; S Koussa; T Maisonobe; J Loiselet; A Mégarbané; M Claustres
Journal:  Am J Hum Genet       Date:  2000-06-02       Impact factor: 11.025

6.  Late-onset Charcot-Marie-Tooth disease 4F caused by periaxin gene mutation.

Authors:  Shoko Tokunaga; Akihiro Hashiguchi; Akiko Yoshimura; Kengo Maeda; Takashi Suzuki; Hiroyo Haruki; Tomonori Nakamura; Yuji Okamoto; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-08-01       Impact factor: 2.660

7.  Intermolecular disulfide bond in the dimerization of S-periaxin mediated by Cys88 and Cys139.

Authors:  Yan Yang; Yemei Ren; Yawei Shi
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-03-02       Impact factor: 3.848

8.  Two novel mutations in the GDAP1 and PRX genes in early onset Charcot-Marie-Tooth syndrome.

Authors:  M Auer-Grumbach; C Fischer; L Papić; E John; B Plecko; R E Bittner; G Bernert; T R Pieber; G Miltenberger; R Schwarz; C Windpassinger; F Grill; V Timmerman; M R Speicher; A R Janecke
Journal:  Neuropediatrics       Date:  2008-02       Impact factor: 1.947

9.  The use of whole-exome sequencing to disentangle complex phenotypes.

Authors:  Hywel J Williams; John R Hurst; Louise Ocaka; Chela James; Caroline Pao; Estelle Chanudet; Francesco Lescai; Horia C Stanescu; Robert Kleta; Elisabeth Rosser; Chiara Bacchelli; Philip Beales
Journal:  Eur J Hum Genet       Date:  2015-06-10       Impact factor: 4.246

10.  Expression of periaxin (PRX) specifically in the human cerebrovascular system: PDZ domain-mediated strengthening of endothelial barrier function.

Authors:  Michael M Wang; Xiaojie Zhang; Soo Jung Lee; Snehaa Maripudi; Richard F Keep; Allison M Johnson; Svetlana M Stamatovic; Anuska V Andjelkovic
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.